Jörgen Ekström

Corporate Officer/Principal bei University of Gothenburg

Consumer Services

Health Technology

Profil

Jörgen Ekström was the founder of Calabar AB, which was founded in 1999, where he held the title of Director from 1999 to 2009.
Currently, he holds the title of Professor at the University of Gothenburg.
In the past, he held the title of Faculty Member at the University of Lund.

Aktive Positionen von Jörgen Ekström

Unternehmen	Position	Beginn
University of Gothenburg	Corporate Officer/Principal	24.01.2011

Alle aktiven Positionen von Jörgen Ekström

Ehemalige bekannte Positionen von Jörgen Ekström

Unternehmen	Position	Ende
University of Lund	Corporate Officer/Principal	-
Calabar AB Calabar AB Medical SpecialtiesHealth Technology Calabar AB is a privately-held company committed to developing a pharmaceutical product addressing the great unmet needs of xerostomia, dry mouth. The company develops XALIEVE™ a locally administered formulation of the cholinesterase inhibitor physostigmine, which been shown to effectively increase salivary flow. Unlike systemically administered drugs, the local route of administration significantly limits adverse events. The compound is currently undergoing Phase II repeated dose studies and Calabar is actively looking for partners to take the compound through phase III. For more information contact Business Development. The company is part of the Karolinska Development AB (publ) portfolio.	Gründer	-

Sehen Sie sich die Erfahrung von Jörgen Ekström im Detail an

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Jörgen Ekström im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Private Unternehmen	1
Calabar AB Calabar AB Medical SpecialtiesHealth Technology Calabar AB is a privately-held company committed to developing a pharmaceutical product addressing the great unmet needs of xerostomia, dry mouth. The company develops XALIEVE™ a locally administered formulation of the cholinesterase inhibitor physostigmine, which been shown to effectively increase salivary flow. Unlike systemically administered drugs, the local route of administration significantly limits adverse events. The compound is currently undergoing Phase II repeated dose studies and Calabar is actively looking for partners to take the compound through phase III. For more information contact Business Development. The company is part of the Karolinska Development AB (publ) portfolio.	Health Technology